| http://purl.uniprot.org/citations/33607071 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/33607071 | http://www.w3.org/2000/01/rdf-schema#comment | "Omentin-1, a newly identified adipokine, has recently been revealed as a novel biomarker for ischemic stroke (IS). Low circulating omentin-1 levels could indicate a high risk of IS, and elevated omentin-1 levels exert a favorable impact on cerebral ischemia. Furthermore, omentin-1 has anti-atherosclerotic, anti-inflammatory, and cardiovascular protective capabilities through the intracellular Akt/AMP-activated protein kinase (AMPK)/ nuclear factor-κB (NF-κB) and certain protein kinase (ERK, JNK, and p38) signaling pathways. Omentin-1 also alleviates endothelial cell dysfunction, improves revascularization via the Akt-endothelial nitric-oxide synthase (eNOS) regulatory axis, promotes endothelium-dependent vasodilation through endothelium-derived NO in an eNOS fashion, and inhibits VSMC proliferation by means of AMPK/ERK signaling pathways, VSMC migration via inactivation of the NADPH oxidase (NOX)/ROS/p38/HSP27 pathways and artery calcification via the PI3K-Akt pathway. These findings indicate that omentin-1 may be a negative mediator of IS. Pharmacologically, several lines of clinical evidence indicate that metformin and statins could elevate omentin-1 levels, although the specific mechanism has not been precisely delineated until now. This study is the first to summarize the comprehensive mechanisms between omentin-1 and atherosclerosis and to review the shielding effect of omentin-1 on IS. We shed light on omentin-1 as a novel therapeutic target for combating IS."xsd:string |
| http://purl.uniprot.org/citations/33607071 | http://purl.org/dc/terms/identifier | "doi:10.1016/j.cca.2021.02.004"xsd:string |
| http://purl.uniprot.org/citations/33607071 | http://purl.uniprot.org/core/author | "Lin S."xsd:string |
| http://purl.uniprot.org/citations/33607071 | http://purl.uniprot.org/core/author | "Li X."xsd:string |
| http://purl.uniprot.org/citations/33607071 | http://purl.uniprot.org/core/author | "Zhang Y."xsd:string |
| http://purl.uniprot.org/citations/33607071 | http://purl.uniprot.org/core/author | "Zhang J."xsd:string |
| http://purl.uniprot.org/citations/33607071 | http://purl.uniprot.org/core/date | "2021"xsd:gYear |
| http://purl.uniprot.org/citations/33607071 | http://purl.uniprot.org/core/name | "Clin Chim Acta"xsd:string |
| http://purl.uniprot.org/citations/33607071 | http://purl.uniprot.org/core/pages | "31-40"xsd:string |
| http://purl.uniprot.org/citations/33607071 | http://purl.uniprot.org/core/title | "Omentin-1: Protective impact on ischemic stroke via ameliorating atherosclerosis."xsd:string |
| http://purl.uniprot.org/citations/33607071 | http://purl.uniprot.org/core/volume | "517"xsd:string |
| http://purl.uniprot.org/citations/33607071 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/33607071 |
| http://purl.uniprot.org/citations/33607071 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/33607071 |
| http://purl.uniprot.org/uniprot/#_Q5IWS5-mappedCitation-33607071 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/33607071 |
| http://purl.uniprot.org/uniprot/#_Q8WWA0-mappedCitation-33607071 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/33607071 |
| http://purl.uniprot.org/uniprot/Q8WWA0 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/33607071 |
| http://purl.uniprot.org/uniprot/Q5IWS5 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/33607071 |